Impact of Hemodialysis on Exhaled Volatile Organic Compounds in End Stage Renal Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01684228|
Recruitment Status : Completed
First Posted : September 12, 2012
Last Update Posted : May 7, 2015
End stage renal disease (ESRD) is a severe clinical state of irreversible loss of endogenous kidney function, shortening life expectancy, if left untreated. In the state of ESRD, over 5000 uremic toxins are accumulated in the body causing dysfunction of various organ systems. The survival of these patients depends on renal replacement therapies, such as hemodialysis (HD), which artificially purifies the blood from toxins. The investigators assume that some of the uremic toxins are also present in the patient's exhaled breath, and could be detected by a non-invasive and highly sensitive test: a NA-NOSE artificial olfactory system. It is based on analysis of volatile organic compounds (VOCs), a novel, non-invasive field in medical diagnostics. The NA-NOSE is made from an array of nanosensors, and was developed by our collaborator Dr. Hossam Haick (Chemical Engineering, Technion).
In the current study, the investigators utilize this technology to identify VOCs in the exhaled breath of dialysis patients, and to characterize certain patterns of expression that could potentially help in future monitoring of HD adequacy. The investigators plan to collect 150 breath samples from patients before and during dialysis, and from healthy subjects. All participants provide a signed informed consent. Subsequently, analysis of samples will be done at Dr. Haick's laboratory, using Gas-Chromatography/Mass-Spectrometry and parameters extracted from each sensor response.
|Condition or disease|
|End Stage Renal Disease|
|Study Type :||Observational|
|Actual Enrollment :||37 participants|
|Observational Model:||Case Control|
|Official Title:||Impact of Hemodialysis on Exhaled Volatile Organic Compounds in End Stage Renal Disease|
|Study Start Date :||August 2010|
|Actual Primary Completion Date :||September 2012|
|Actual Study Completion Date :||September 2012|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01684228
|Rambam Health Care Campus|
|Haifa, Israel, 31096|
|Principal Investigator:||Suheir Assady, MD, Ph.D||Department of Nephrology, Rambam-Health Care Campus|